On May 15, 2015, Respironics, Inc., a Philips business, provided the following response to ResMed's Update on Phase IV SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy in Central Sleep Apnea ...

ResMed, Inc. RMD recently introduced its AirCurve 11 series devices -- the company’s newest bilevel devices that use two levels of support, inspiratory positive airway pressure (IPAP) and expiratory ...

Primary results from ResMed Inc.’s RMD CAT-HF trial showcased the significance of adaptive servo-ventilation (ASV) therapy in the treatment of heart failure (HF). Data were presented at the European ...

Cardiovascular problems can be associated with sleep apnea, and it's commonly assumed that treatment of sleep apnea could have cardiovascular benefits. But a ResMed ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Study Overview: ResMed Inc. has initiated ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: SERVE-HF ...

ResMed has struggled to bounce back from the shock failure of a clinical trial in May, which pushed its shares down 18 per cent, and it is still trading down more than 11 per cent on its May price.

- Safety Signal of Increased Cardiovascular Mortality Found For ASV Therapy In People With Predominant Central Sleep Apnea and Symptomatic Chronic Heart Failure - Results and Safety Signal Observed ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...